Who makes [14C]-AQX-1125 IV?

[14C]-AQX-1125 IV is developed by Aquinox Pharmaceuticals (Canada) Inc..

What development phase is [14C]-AQX-1125 IV in?

[14C]-AQX-1125 IV is in Phase 1.

Last reviewed 2026-05-15 · How we verify

[14C]-AQX-1125 IV

Aquinox Pharmaceuticals (Canada) Inc. · Phase 1 active Small molecule

At a glance

Generic name	[14C]-AQX-1125 IV
Also known as	Radiolabelled AQX-1125 IV
Sponsor	Aquinox Pharmaceuticals (Canada) Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[14C]-AQX-1125 IV CI brief — competitive landscape report
[14C]-AQX-1125 IV updates RSS · CI watch RSS
Aquinox Pharmaceuticals (Canada) Inc. portfolio CI